Persomed has partnered up with QbD, myNEO, VUB, and UZA to further persue its primary goal: bringing personalized cancer vaccines closer to every patient. Together we aim to validate the current Persomed Tetramix-DC-NEO technology platform in a first clinical phase I study in mMSS-CRC patients and, in parallel, we will continue to strive to develop a robust automated and digitally supported workflow for personalized cancer vaccine production building on the expertise and inte